
Stifel initiated coverage of City Therapeutics (CTY) with a Buy rating and $34 price target The firm says the company has a “differentiated” siRNA pipeline. Stifel is mow enthusiastic about
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CTY | City Therapeutics, Inc. | 19.32 | -4.26 | -18.08% |
| Name | Price | % Change | |
|---|---|---|---|
| $19.32 | -18.08% |

Stifel initiated coverage of City Therapeutics (CTY) with a Buy rating and $34 price target The firm says the company has a “differentiated” siRNA pipeline. Stifel is mow enthusiastic about

Jefferies analyst Maury Raycroft initiated coverage of City Therapeutics (CTY) with a Buy rating and $32 price target City is a next-generation RNAi platform company led by former Alnylam (ALNY)

Goldman Sachs initiated coverage of City Therapeutics (CTY) with an Early-Stage Biotech and no price target The company is developing RNA-interference therapeutics for large-market and rare disease indications, the analyst

Oppenheimer initiated coverage of City Therapeutics (CTY) with an Outperform rating and $46 price target. The company, which is developing siRNA medicines, was co-founded by Alnylam’s (ALNY) founding CEO, who

City Therapeutics (CTY) announced that the first participant has been dosed in the Phase 1 clinical trial of CITY-RBP4, an investigational RNAi therapeutic candidate for the treatment of Stargardt disease

City Therapeutics, Inc. ( ($CTY) ) has provided an announcement. On November 10, 2026, City Therapeutics announced that the first participant had been dosed in the Phase 1 trial of

City Therapeutics, Inc. (CTY) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Paul Matteis. Paul Matteis’s rating is based on City’s differentiated siRNA pipeline and the substantial

Maury Raycroft, an analyst from Jefferies, has initiated a new Buy rating on City Therapeutics, Inc. (CTY). Maury Raycroft’s rating is based on a combination of a seasoned RNAi leadership

Biotech listings continued to build momentum as City Therapeutics and Iambic Therapeutics made their market debuts, highlighting investor interest in RNA based therapies and AI enabled drug development. LATEST IPOS

City Therapeutics (CTY), a clinical-stage biotechnology company that says it is “developing the next generation of RNA interference therapeutics,” priced its upsized initial public offering of 11.11M shares of its
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.